# CCA Cancer Care AI OS V12.2-PC1.9 — Structural Conformance Phase 7

> **Release boundary:** PC1.9 is a reconstructed descendant built from the latest full local PC1.5 package plus the previously documented PC1.6–PC1.8 structural deltas/evidence. The standalone PC1.6–PC1.8 acceptance scripts were not present in the active runtime and are **not** claimed as freshly rerun. Their high-value reconstructed behaviors are exercised again by the PC1.9 Phase-7 suite.

> Synthetic clinical values remain QA/demo-only. Use **Clinician Review Mode** for stakeholder review. NEXUS / Guideline Pathway / Staging decision support remains frontend-only as previously agreed; this release does not claim NCCN/NEXUS clinical reasoning.

## PC1.9 focus

- distinct **Intake Nurse** and **MDT Chair** role contracts;
- governed diagnostic ordering with a mandatory clinician reason;
- final laboratory result provenance, governed abnormal flags and read-only server-owned reference-range semantics ready for later LIS binding;
- Coordinator → MDT Chair recommendation/sign-off separation, including invalidation of a prior Chair signature after resubmission;
- measurement-first response assessment with separate Medical Oncology confirmation;
- derived post-operative adjuvant-review readiness and downstream work items;
- minimum-necessary Front Desk consent-completion visibility;
- continued signed-record immutability, role scoping and audit/version semantics.

See `V12_2_PC1_9_STRUCTURAL_CONFORMANCE_SUMMARY.md`, `V12_2_PC1_9_REMAINING_GATES.md`, and `V12_2_PC1_9_VALIDATION_RESULTS.json` for this descendant's current evidence.

---

# Historical PC1.1 / V12.2 documentation
> PC1 layers clinician-facing oncology workflow/content structures over the frozen V12.2 defect-remediation core. Synthetic clinical values remain QA/demo-only. Use **Clinician Review Mode** for stakeholder review; use **Product Test Mode** only for synthetic workflow execution. NEXUS-NCCN is frontend-only in this package.

See `V12_2_PC1_PRE_CLINICIAN_SUMMARY.md`, `PC1_PRE_CLINICIAN_REMAINING_GATES.md`, and `V12_2_PC1_RELEASE_CHECKLIST.md` first.

---

# CCA Cancer Care HIS + Oncology EMR — V12.2 Final Defect Remediation

A self-contained, clickable oncology HIS/EMR product-test build focused on **end-to-end oncology workflow execution, role-scoped access, governed content, exact order-to-delivery reconciliation, longitudinal history, OPD/IPD continuity and server-enforced safety/state rules**.

V12.2 is a **defect-remediation release**, not a feature-expansion release. It was produced from the V12 exhaustive validation findings and then rerun through the requested remediation, process, regression and 41-scenario suites.

## Golden workflow

**Registration → Nurse Intake → Medical Oncology → Diagnostics → MDT → Treatment Plan → Treatment Order → Pharmacy → Day Care / IPD MAR → Toxicity → Readiness → Response / Reassessment**, with separate **Radiation Oncology**, **Surgical Oncology**, **Patient Journey**, **Finance**, **Care Coordination**, and **Clinical Content Master** workflows.

Treatment Plan, Treatment Order, Pharmacy verification/preparation/dispense and actual Administration remain distinct records and state transitions.

## V12.2 remediation focus

This release hardens defects found in the V12 readiness audit, including:

- finalized radiology/pathology/lab immutability and amendment semantics;
- active/orderable clinical-content immutability and versioning;
- optimistic locking / stale-write rejection;
- server-side logout/token revocation and patient-access scoping;
- governed queue destinations and appointment/no-show routing;
- inpatient systemic treatment discharge blocking while orders remain unresolved;
- death/episode-closure propagation to active therapy and future work;
- critical laboratory-result task routing and rejected-specimen/recollection flow;
- non-TNM disease-classification support without fake TNM values;
- safer document upload/content handling;
- idempotent finance/payment operations where implemented;
- episode close/reopen linkage and historical report-version retrieval;
- server-side laboratory unit normalization and plausibility validation.

### Laboratory plausibility protection

Laboratory write validation now performs explicit unit handling and broad **product-test plausibility checks** before a Final result is accepted. These checks are data-quality/transcription guards, not treatment criteria.

Examples exercised in the fresh acceptance run:

- `ANC 999999 ×10^9/L` → rejected;
- `ANC 350 ×10^9/L` → rejected;
- `ANC 3.5 ×10^9/L` → accepted;
- `ANC 800 cells/µL` → accepted, normalized to `0.8 ×10^9/L` for readiness evaluation.

Treatment-readiness thresholds remain server-owned by the exact governed regimen/version rather than supplied by the client.

## Synthetic institutional product-test content

To remove artificial scenario blocks during product testing, V12.2 includes an explicitly synthetic CCA institutional test-content pack. It exists **only to exercise software behavior** and must not be interpreted as patient-care guidance or CCA-approved clinical policy.

The synthetic QA pack contains:

- **53** active product-test templates:
  - **21** orderable systemic-regimen templates;
  - **16** Radiation Oncology templates;
  - **14** Surgical Oncology templates;
  - **2** continuous-therapy templates;
- **5** synthetic formulary items used for fixed-dose, BSA, weight, AUC and oral/continuous workflow testing.

Together with the original synthetic `REG-CCA-TCHP-DEMO`, a reset runtime exposes **22 active/orderable synthetic/demo systemic regimens** for process testing.

Historical/open-source regimen imports remain reference-only and non-orderable unless separately cloned and governed.

## Fresh validation result

All requested executable V12.2 suites passed in isolated reset runtimes:

| Suite | Result |
|---|---:|
| Targeted defect-remediation reproductions | **38 PASS / 0 FAIL** |
| V12 process + IPD acceptance | **48 PASS / 0 FAIL** |
| Full legacy/regression suite | **94 PASS / 0 FAIL** |
| Supplied process scenario pack | **41 / 41 CASE PASS** |
| 41-case preflight | **0 failures** |
| 41-case audit-chain verification | **200 / 0 audit errors** |

These suites overlap. Their counts must **not** be added and described as unique requirements.

Canonical evidence is under `validation_evidence/`. See `VALIDATION.md` for interpretation and limits.

## Browser/UI verification status

`static/app.js` passes JavaScript syntax validation and the backend/test scripts pass Python compilation. A managed headless-Chromium run in this execution environment could not complete against localhost because of the container/browser policy/runtime, so **full browser interaction is not claimed as independently executed here**. API/state/persistence/authorization workflows were executed live.

## Run locally

```bash
python3 reset_demo.py
python3 server.py
```

Open: `http://127.0.0.1:8765`

Demo PIN: `2026`

## Product boundary

The prototype owns the longitudinal oncology record and workflow orchestration. It does not replace a TPS/OIS, PACS/RIS, LIS, pharmacy inventory ERP, full inpatient/ICU EHR or production identity platform. External ABDM/HMIS/MOSAIQ/ARIA/LIS/PACS/TPS connections remain integration boundaries unless separately connected.

Regulatory certification, licensing review, NCCN/NEXUS correctness, OPD voice transcription and OCR accuracy are outside this product-test release gate.

**All included patients, clinical values, regimens, RT prescriptions, surgical templates and formulary entries used for demonstration/testing are synthetic. Do not use this build for patient care.**

## V12.2-PC1.2 Mature Oncology UX

This package adds `static/pc1_2.js`, a frontend-first clinician workflow redesign on top of the validated V12.2/PC1 runtime. It introduces clean investigation ordering, a multidisciplinary treatment-plan builder, patient-readable treatment orders, grouped readiness, pharmacy/day-care execution views, planned-vs-delivered RT, plan-vs-operative surgical views, and expanded oral therapy. NEXUS remains frontend-only. See `V12_2_PC1_2_MATURE_ONCOLOGY_UX_SUMMARY.md`.

---

## V12.2-PC1.4 Structural Conformance Phase 2

PC1.4 is a descendant structural-remediation build driven by `CCA_Clinical_Data_Ownership_Input_Register_v1.1`. It preserves the mature PC1.2 clinician UX and PC1.3 unit/visibility controls while adding:

- explicit DECIDED semantics for final ordered dose,
- governed allergy structure and medication-reconciliation attestation,
- governed fall-risk scale + server-derived risk level,
- explicit Treatment Order supersession and stale-order blocking,
- version-bound RT prescription/plan/Physics/RO approval and fraction traceability,
- `static/pc1_4.js` clinician-facing controls for these structures.

Clinical values remain Synthetic QA or `NEEDS CCA DECISION` unless institutionally approved. See `V12_2_PC1_4_STRUCTURAL_CONFORMANCE_SUMMARY.md`, `TRACK_B_PHASE2_REMEDIATION.md` and `V12_2_PC1_4_REMAINING_GATES.md`.
